中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Magnetic Resonance Spectroscopy (MRS) in Midlife Depression

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态
赞助商
Emory University
合作者
National Institute of Mental Health (NIMH)

关键词

抽象

The purpose of this study is to determine the impact of inflammation on central nervous system (CNS) glutamate, white matter pathology and alterations in behavior and cognition in middle-aged patients with major depression. Depression is associated with significant alterations in glutamate concentrations and white matter integrity, which has been associated with decreased antidepressant response, poor functional outcome, and cognitive impairment.

描述

This study involves behavioral assessments, neurocognitive testing, blood sampling and magnetic resonance imaging (MRI) scanning. Goals of this study are to determine the impact of inflammation on glutamate concentrations in the basal ganglia and on the integrity of white matter tracts in the basal ganglia and other subcortical regions of middle-aged depressed versus non-depressed individuals and to associated the impact of glutamate and white matter changes on behavioral symptoms among the same group of patients.

日期

最后验证: 04/30/2020
首次提交: 09/28/2015
提交的预估入学人数: 09/30/2015
首次发布: 10/01/2015
上次提交的更新: 05/06/2020
最近更新发布: 05/10/2020
实际学习开始日期: 06/30/2016
预计主要完成日期: 11/30/2020
预计完成日期: 11/30/2020

状况或疾病

Depression
Depression Bipolar

-

手臂组

干预/治疗
Participants with Major Depression
Participants with major depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
Participants without Depression
Participants without depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.

资格标准

有资格学习的年龄 35 Years 至 35 Years
有资格学习的性别All
取样方式Non-Probability Sample
接受健康志愿者
标准

Inclusion Criteria for Participants with Depression:

- Willing and able to give written informed consent

- Meet criteria for Major Depression per DSM-V criteria using Structured Clinical Interview for DSM-V (SCID-V) and a score ≧18 on the 17-item Hamilton Rating Scale for Depression (HAMD).

- Absence of significant suicidal ideation, determined by the Columbia Suicide Severity Rating Scale - Screen Version (CSSRS)

- Meets MRI scanning safety requirements:

- Absence of embedded MR-unsafe metallic objects

- Location and quantity of MR-safe metallic objects will minimally impact rigor/reproducibility standards of the MR data (as determined by the PI in consultation with the neuroimaging team)

Specific Inclusion Criteria for Controls:

- Criteria for major depression not met per the SCID-V

- HAMD scores ≦7

- Absence of any Axis I pathology

Exclusion Criteria:

- Unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease as evidenced by any of the following:

- Clinically significant abnormalities in lab values, medical history and physical exam as determined by PI or their designee

- Changes in medications prescribed for chronic medical illnesses within past 4 weeks,

- Hospitalization or drastic medical changes within past 4 weeks

- Cognitive impairment as defined by:

- Score of < 28 on Mini-mental exam (MMSE)

- Below 8th grade reading ability as defined by Wide Range Achievement Test-3 (WRAT3) score

- Presence of psychosis (lifetime) / mania (current) as defined by:

- Lifetime diagnosis of psychotic disorders SCID-V

- SCID-V criteria for current mania/hypomania within the current episode

- Clinically significant substance abuse within the past 6 months as defined by meeting the SCID-V threshold of severity for > 4/11 criteria for substance abuse disorder

- Presence of active symptoms of an eating disorder as defined by:

- SCID-V diagnosis of Anorexia or bulimia nervosa.

- Binge eating and/or purging behavior in the absence of mood alterations or precipitating stress (bingeing within the current episode of mood symptoms will not be exclusionary)

- Presence of significant psychiatric comorbidities during current episode:

- Primary diagnosis of anxiety-spectrum disorders (panic, generalized anxiety, social phobia etc.), PTSD, OCD based on SCID-V criteria

- Severity of above diagnoses exceeds that of major depression based on assessments by the PI and the Study Team members

- Severe Axis II personality pathology as determined by a clinician

- Use of immune-active medications:

- Continuous use of prescribed, standard dose non-steroidal anti-inflammatory (NSAIDs) excluding 81 mg of aspirin within past 1 week and PRN use of NSAIDs within past 72 hours

- Intake of antibiotics within the past 2 weeks

- Immunization (including seasonal flu) within the past 2 weeks

- Use of topical or inhaled steroids within 72 hours unless otherwise approved by PI

- Use of systemic steroids (oral or parenteral) within past 6 months

- Patients taking herbal supplements with currently known effects on immune system including omega-3 supplements within 2 weeks or probiotics prior to research blood draws and scan unless approved by PI.

- Use of psychotropics:

- Daily intake of standard doses of antidepressants, mood stabilizers, antipsychotics, psychostimulants within 2 weeks (8 weeks for fluoxetine) prior to initiation of study procedures (scan and research blood sampling)

- Daily/clinically significant use of sedative-hypnotics and tranquilizers and opiates as determined by PI

- PRN use of sedative/hypnotics, benzodiazepines exceeding equivalent of clonazepam 1mg within 48 hours of study visit.

- Cancer and autoimmunity:

- Life time history of diagnosis and/or treatment of cancers other than basal cell carcinoma

- Life time history of diagnosis and/or treatment of autoimmune disorders including but not restricted to multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, and Hashimoto's thyroiditis

结果

主要结果指标

1. Levels of Glutamate in the basal ganglia [Day 1 (Day after Screening)]

Single-voxel MRS (Magnetic Resonance Spectroscopy) scans will be done to determine the glutamate levels in the basal ganglia. MRS uses a magnetic field to look at magnetic nuclei which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra, the structure and concentrations of metabolite can be determined.

次要成果指标

1. Neurocognitive Testing [Day 1 (Day after Screening)]

The Cambridge Neuropsychological Test Automated Battery (CANTAB) instrument will be used to evaluate multiple cognitive domains including reaction time, attention and information processing. Findings will be compared between depressed participants and healthy controls.

2. Hamilton Rating Scale for Depression (HAM-D-17) Score [Day 1 (Day after Screening)]

Clinician rated depression will be examined with the Hamilton Rating Scale for Depression (HAM-D-17). The HAM-D-17 is a 17-item scale used to assess present-state depression. Responses are on a 3 or 5-point scale (depending on the item) where 0 = absence of the problem and 3 or 5 = severe problem. Total raw scores range from 0 to 50 where higher scores indicate increased symptoms of depression.

3. Disease affecting white matter connecting frontal cortex to other regions of the brain [Day 1 (Day after Screening)]

Diffusion tensor imaging (DTI) scans will be obtained to to study white matter disease in frontal cortex.

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge